09 October 2025
: Case report 
Successful Management of Refractory Pulmonary Mucormycosis Using Intracavitary Amphotericin B: A Case Report and Literature Review
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Educational Purpose (only if useful for a systematic review or synthesis)
Yujie Gao ADEF 1,2, Hansheng Wang
CEF 1,2, Xiao feng Bai C 2, Yi Wu B 2, Xiaobing Li E 2, Meifang Wang CE 1,2, Fahim kanani E 1,2*
DOI: 10.12659/AJCR.949413
Am J Case Rep 2025; 26:e949413
Table 1 Clinical timeline summary.
| Dates | Interventions | Chest CT results |
|---|---|---|
| June 12, 2023 (HD1) | Anti-infective treatment at another hospital | Multiple inflammatory lesions in both lungs |
| June 16, 2023 (HD4) | Admitted and treated with meropenem combined with linezolid for 4 days | Multifocal inflammatory lesions with cavitation and left pleural effusion |
| June 26, 2023 (HD14) | Central venous infusion of amphotericin B, antibiotics adjusted to piperacillin-tazobactam combined with moxifloxacin for 10 days | Pulmonary lesion progression |
| July 6, 2023 (HD25) | Added posaconazole infusion and nebulized amphotericin B for 11 days | No significant changes in pulmonary lesions compared to previous CT |
| July 31, 2023 (HD50) | 12 days after the first intrapulmonary injection of amphotericin B | Bilateral pulmonary nodules/cavities showed significant regression |
| August 17, 2023 | 16 days after the second intrapulmonary injection of amphotericin B | Pulmonary lesions showed improved resolution with no pleural effusion |
| September 26, 2024 | Under follow-up | Complete resolution of pulmonary inflammation |